Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tarsus Pharmaceuticals (TARS) Shares Outstanding (Diluted Average): 2020-2024

Historic Shares Outstanding (Diluted Average) for Tarsus Pharmaceuticals (TARS) over the last 5 years, with Dec 2024 value amounting to $37.6 million.

  • Tarsus Pharmaceuticals' Shares Outstanding (Diluted Average) rose 11.01% to $42.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.6 million, marking a year-over-year increase of 11.01%. This contributed to the annual value of $37.6 million for FY2024, which is 27.98% up from last year.
  • Tarsus Pharmaceuticals' Shares Outstanding (Diluted Average) amounted to $37.6 million in FY2024, which was up 27.98% from $29.4 million recorded in FY2023.
  • Tarsus Pharmaceuticals' Shares Outstanding (Diluted Average)'s 5-year high stood at $37.6 million during FY2024, with a 5-year trough of $6.2 million in FY2020.
  • Moreover, its 3-year median value for Shares Outstanding (Diluted Average) was $29.4 million (2023), whereas its average is $30.5 million.
  • Data for Tarsus Pharmaceuticals' Shares Outstanding (Diluted Average) shows a peak YoY skyrocketed of 231.12% (in 2021) over the last 5 years.
  • Tarsus Pharmaceuticals' Shares Outstanding (Diluted Average) (Yearly) stood at $6.2 million in 2020, then surged by 231.12% to $20.6 million in 2021, then rose by 19.78% to $24.6 million in 2022, then climbed by 19.35% to $29.4 million in 2023, then increased by 27.98% to $37.6 million in 2024.